Tirzepatide – 10 mg.

It is primarily used for type 2 diabetes and medical weight management, and in clinical studies it has shown remarkable results for both. Patients receiving Tirzepatide often experience substantial weight loss, with some trials showing reductions of 15% to over 20% of total body weight, depending on the dosage and duration of treatment. In addition to weight reduction, it significantly improves blood-glucose levels, lowers A1C, reduces insulin resistance, and may improve cardiovascular risk markers. Because of these effects, Tirzepatide has quickly become one of the most impactful metabolic medications available today.

Tirzepatide is administered as a once-weekly subcutaneous injection. Treatment usually begins at a low dose, such as 2.5 mg weekly, and gradually increases over several weeks to help reduce side effects. Common therapeutic doses range from 5 mg to 15 mg weekly, depending on the patient’s response and the purpose of treatment (diabetes management vs. weight loss). As with other incretin-based drugs, the most frequent side effects are gastrointestinal—nausea, vomiting, diarrhea, constipation, or stomach discomfort—especially during dose escalation. While it is an approved medication, it should be used exactly as prescribed, since improper dosing or unregulated versions can carry significant risks.

Overall, Tirzepatide is considered one of the most effective medications currently available for improving metabolic health, offering powerful benefits for both blood-sugar control and weight reduction. Its dual-hormone mechanism provides a comprehensive and long-lasting impact, making it a major advancement in the treatment of obesity and type 2 diabetes.